Pegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3298-3308

  Morris, Christopher J ^a,c   Beck, Konrad ^a   Fox, Marc A ^b   Ulaeto, David ^b   Clark, Graeme C ^b   Gumbleton, Mark ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CECROPIN A;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL VIRULENCE; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING AND TRANSPORT; DRUG INCOMPATIBILITY; EX VIVO STUDY; FLUORESCENCE SPECTROSCOPY; IC 50; IN VITRO STUDY; LUNG EDEMA; LUNG INFECTION; LUNG PARENCHYMA; MALE; NONHUMAN; PERMEABILITY BARRIER; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN CONFORMATION; RAT;

ANIMALS; ANTI-INFECTIVE AGENTS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCULAR DICHROISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; LUNG; MALE; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TESTS; PEPTIDES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, FLUORESCENCE;

EID: 84861133663     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06335-11     Document Type: Article

References (48)

1. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY. 2009. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr. Biol. (Camb.) 1:371-381.
2. Barar J, et al. 2007. Cell selective glucocorticoid induction of caveolin-1 and caveolae in differentiating pulmonary alveolar epithelial cell cultures. Biochem. Biophys. Res. Commun. 359:360-366. (Pubitemid 46880513)
3. Bartlett KH, McCray PB, Jr, Thorne PS. 2003. Novispirin G10-induced lung toxicity in a Klebsiella pneumoniae infection model. Antimicrob. Agents Chemother. 47:3901-3906. (Pubitemid 37485006)
4. Bend JR, Serabjit-Singh CJ, Philpot RM. 1985. The pulmonary uptake, accumulation, and metabolism of xenobiotics. Annu. Rev. Pharmacol. Toxicol. 25:97-125. (Pubitemid 15090976)
5. Bergsson G, et al. 2009. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J. Immunol. 183:543-551.
6. Brogden KA, et al. 2001. The ovine cathelicidin SMAP29 kills ovine respiratory pathogens in vitro and in an ovine model of pulmonary infection. Antimicrob. Agents Chemother. 45:331-334. (Pubitemid 32039140)
7. Buck M. 1998. Trifluoroethanol and colleagues: cosolvents come of age. Recent studies with peptides and proteins. Q. Rev. Biophys. 31:297-355. (Pubitemid 29213772)
8. Byron PR, Roberts NS, Clark AR. 1986. An isolated perfused rat lung preparation for the study of aerosolized drug deposition and absorption. J. Pharm. Sci. 75:168-171. (Pubitemid 16162541)
9. Campbell L, et al. 1999. Caveolin-1 expression and caveolae biogenesis during cell transdifferentiation in lung alveolar epithelial primary cultures. Biochem. Biophys. Res. Commun. 262:744-751. (Pubitemid 29443729)
10. Chen GC, Yang JT. 1977. Two-point calibration of circular dichrometer with d-10-camphorsulfonic acid. Anal. Lett. 10:1195-1207.
11. Cudic M, et al. 2002. Development of novel antibacterial peptides that kill resistant isolates. Peptides 23:2071-2083. (Pubitemid 36092040)
12. Dawson RM, McAllister J, Liu CQ. 2010. Characterisation and evaluation of synthetic antimicrobial peptides against Bacillus globigii, Bacillus anthracis and Burkholderia thailandensis. Int. J. Antimicrob. Agents 36:359-363.
13. Dean RE, et al. 2010. A carpet-based mechanism for direct antimicrobial peptide activity against vaccinia virus membranes. Peptides 31:1966-1972.
14. Fonseca SB, Pereira MP, Kelley SO. 2009. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev. 61:953-964.
15. Fox MA, Thwaite JE, Ulaeto DO, Atkins TP, Atkins HS. 2012. Design and characterization of novel hybrid antimicrobial peptides based on cecropin A, LL-37 and magainin II. Peptides 33:197-205.
16. Guiotto A, et al. 2003. PEGylation of the antimicrobial peptide nisin A: problems and perspectives. Farmaco 58:45-50. (Pubitemid 38365970)
17. Gumbleton M. 2001. Caveolae as potential macromolecule trafficking compartments within alveolar epithelium. Adv. Drug Deliv. Rev. 49:281-300. (Pubitemid 32718689)
18. Imura Y, Nishida M, Matsuzaki K. 2007. Action mechanism of PEGylated magainin 2 analogue peptide. Biochim. Biophys. Acta 1768:2578-2585. (Pubitemid 47532037)
19. Imura Y, Nishida M, Ogawa Y, Takakura Y, Matsuzaki K. 2007. Action mechanism of tachyplesin I and effects of PEGylation. Biochim. Biophys. Acta 1768:1160-1169. (Pubitemid 46550351)
20. Jacob MK, Leena S, Kumar KS. 2008. Peptide-polymer biotherapeutic synthesis on novel cross-linked beads with "spatially tunable" and "isolated"functional sites. Biopolymers 90:512-525.
21. Jenssen H, Hamill P, Hancock RE. 2006. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19:491-511. (Pubitemid 44137212)
22. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B. 1998. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem. 273:3718-3724. (Pubitemid 28109800)
23. Lisanby MW, et al. 2008. Cathelicidin administration protects mice from Bacillus anthracis spore challenge. J. Immunol. 181:4989-5000.
24. Loose C, Jensen K, Rigoutsos I, Stephanopoulos G. 2006. A linguistic model for the rational design of antimicrobial peptides. Nature 443:867-869. (Pubitemid 44622698)
25. Luo P, Baldwin RL. 1997. Mechanism of helix induction by trifluoroethanol: a framework for extrapolating the helix-forming properties of peptides from trifluoroethanol/water mixtures back to water. Biochemistry 36:8413-8421. (Pubitemid 27297553)
26. McAllister SM, Alpar HO, Teitelbaum Z, Bennett DB. 1996. Do interactions with phospholipids contribute to the prolonged retention of polypeptides within the lung? Adv. Drug Deliv. Rev. 19:89-110. (Pubitemid 26169869)
27. Morris CJ, Smith MW, Griffiths PC, McKeown NB, Gumbleton M. 2011. Enhanced pulmonary absorption of a macromolecule through coupling to a sequence-specific phage display-derived peptide. J. Control. Release 151:83-94.
28. Ohtani T, Murakami M, Yamamoto A, Takada K, Muranishi S. 1991. Effect of absorption enhancers on pulmonary absorption of fluorescein isothiocyanate dextrans with various molecular weights. Int. J. Pharm. 77:141-150.
29. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. 1999. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its noncell- selective activity. Biochem. J. 341(Pt 3):501-513. (Pubitemid 29389178)
30. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. 1995. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4:2411-2423.
31. Ryan G, Mukhopadhyay S, Singh M. 2000. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. CD001021. doi:10.1002/14651858.CD001021.
32. Sakagami M, Byron PR, Rypacek F. 2002. Biochemical evidence for transcytotic absorption of polyaspartamide from the rat lung: effects of temperature and metabolic inhibitors. J. Pharm. Sci. 91:1958-1968. (Pubitemid 36254932)
33. Sakagami M, et al. 2006. Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung. Pharm. Res. 23:270-279. (Pubitemid 43237858)
34. Sarko D, et al. 2010. The pharmacokinetics of cell-penetrating peptides. Mol. Pharm. 7:2224-2231.
35. Sato H, Feix JB. 2006. Peptide-membrane interactions and mechanisms of membrane destruction by amphipathic alpha-helical antimicrobial peptides. Biochim. Biophys. Acta 1758:1245-1256. (Pubitemid 44444829)
36. Scopes RK. 1974. Measurement of protein by spectrophotometry at 205 nm. Anal. Biochem. 59:277-282.
37. Sipos D, Andersson M, Ehrenberg A. 1992. The structure of the mam-malian antibacterial peptide cecropin P1 in solution, determined by proton-NMR. Eur. J. Biochem. 209:163-169.
38. Smith MW, et al. 2007. Phage display identification of functional binding peptides against 4-acetamidophenol (Paracetamol): an exemplified approach to target low molecular weight organic molecules. Biochem. Biophys. Res. Commun. 358:285-291. (Pubitemid 46719114)
39. Svenson J, Brandsdal BO, Stensen W, Svendsen JS. 2007. Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect. J. Med. Chem. 50:3334-3339. (Pubitemid 47065982)
40. Thennarasu S, et al. 2010. Antimicrobial and membrane disrupting activities of a peptide derived from the human cathelicidin antimicrobial peptide LL37. Biophys. J. 98:248-257.
41. Thwaite JE, Hibbs S, Titball RW, Atkins TP. 2006. Proteolytic degradation of human antimicrobial peptide LL-37 by Bacillus anthracis may contribute to virulence. Antimicrob. Agents Chemother. 50:2316-2322. (Pubitemid 43993168)
42. Uhal BD. 1997. Cell cycle kinetics in the alveolar epithelium. Am. J. Physiol. 272:L1031-L1045.
43. Veronese FM, Harris JM. 2002. Introduction and overview of peptide and protein pegylation. Adv. Drug Deliv. Rev. 54:453-456. (Pubitemid 34615541)
44. Wang Y, Agerberth B, Lothgren A, Almstedt A, Johansson J. 1998. Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL-37. J. Biol. Chem. 273:33115-33118. (Pubitemid 29005678)
45. Wang Y, Walter G, Herting E, Agerberth B, Johansson J. 2004. Antibacterial activities of the cathelicidins prophenin (residues 62 to 79) and LL-37 in the presence of a lung surfactant preparation. Antimicrob. Agents Chemother. 48:2097-2100. (Pubitemid 38691604)
46. Zhang G, Han B, Lin X, Wu X, Yan H. 2008. Modification of antimicrobial peptide with low molar mass poly(ethylene glycol). J. Biochem. 144:781-788.
47. Zhang L, et al. 2005. Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob. Agents Chemother. 49:2921-2927. (Pubitemid 40917611)
48. Ziegler A. 2008. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv. Drug Deliv. Rev. 60:580-597. (Pubitemid 351215575)